Product
SNG001
3 clinical trials
2 indications
Indication
SARS-CoV-2Indication
COVID-19Clinical trial
A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19Status: Completed, Estimated PCD: 2021-12-15
Clinical trial
A Randomised Double-blind Placebo-controlled Trial to Determine the Safety and Efficacy of Inhaled SNG001 (IFN-β1a for Nebulisation) for the Treatment of Patients With Confirmed SARS-CoV-2 InfectionStatus: Completed, Estimated PCD: 2021-02-17
Clinical trial
Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)Status: Completed, Estimated PCD: 2022-04-07